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Comparative analysis of plasmid DNA delivery into cells efficiency (with effective agent con-
centration 250 μg/kg), ensuring accumulation of nerve growth factor (NGF) after intramuscu-
lar injection and intramuscular administration using electroporation method on rats was per-
formed. Application of electroporation method ensured over 4 times increase of DNA plas-
mid concentration in muscle tissue within the first hour after its injection and increased the 
duration of its determination. Higher bioavailability parameters were confirmed by 3 times 
increase in gene expression level, encoding NGF accumulation and 3 times increase in con-
centration of the target NGF protein in blood plasma. The results obtained allow us to recom-
mend this method for introduction of NGF plDNA in its biological activity and effectiveness 
in models of nerve damage investigation.
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Introduction 
Steady growth of neurodegenerative disease incidence in overall structure of nervous 
system pathology is observed today [1]. Clinically significant cases of severe decompensa-
tion of nervous system with the progression of Alzheimer and Parkinson diseases become 
widespread in active working age people [2; 3]. 
High probability of peripheral polyneuropathies development is especially acute in 
relation to workers of occupationally harmful industries, such as facilities for production 
and storage of organophosphorous compounds (OPC) or agricultural production. 
The loss of function of the nerves and/or areas of the brain is accompanied by de-
crease in the quality of life, and the most severe forms of damage result in disability of 
patients.
Pharmacological correction of toxic polyneuropathy and encephalopathy involves 
prescription of drugs that improve neuronal conductivity, microcirculation, energoplastic 
and metabotropic processes that produce pathogenetic and symptomatic effect. However, 
even timely start of treatment and use of modern medicines sometimes provides only 
retardation  of disease progression [4]. It is known that development of organophosphate 
peripheral neuropathies is based on neuron and neuronal microenvironment degenera-
tion processes, demyelination of nerve conductors, death of Schwann cells, multiple ax-
onopathies with the release of molecules with antigenic properties into extracellular space 
[5]. These changes result in development of local inflammation and an autoimmune pro-
cess with a transition to a sluggish, progressive form and replacement of nervous tissue 
in lesions by connective tissue [6]. Necessary condition for neuronal tissue regeneration 
after injury (for example, axotomy) is neurotrophins, neuropoietic cytokines, insulin-like 
growth factor and glial cell-derived neurotrophic factor expression.
It seems reasonable to use genetic make-ups on the basis of DNA expressing nerve 
growth factor (NGF) for treatment of nervous system diseases associated with organic 
disturbances (lesions) of nerve conductors [7]. Its neuroprotective effect in Alzheimer’s 
disease has been shown in clinical study conditions. Thus, adeno-associated viral vector, 
used for encoding human NGF (AAV2-NGF) to Meinert’s basal nucleus, ensured safety 
and efficiency of treatment in case of patients with mild disease [8]. High efficiency of 
NGF application was demonstrated for spinal cord injury, especially when combined with 
neurotrophic and neurotrophin-3 factor [9].
NGF provides growth, differentiation and restoration of axons and dendrites, for-
mation of neurons cytoskeleton, exocytosis and functioning of synapses, neuroendocrine 
and immune systems [10]. This factor prevents cell death and stimulates the functional 
activity of basal membrane in cholinergic neurons, improves Schwann cells migration, 
thereby preventing or retarding degenerative processes of the nervous tissue inherent in 
Alzheimer’s disease and toxic polyneuropathy. Due to high molecular weight and charge, 
NGF has a low ability to overcome blood-brain barrier, which requires development of 
effective means of its delivery [11].
More convincing data were obtained when using trophic growth factors, including 
those which were delivered by means of plasmid technology with subsequent expression in 
the body. Plasmids are small double-stranded circular extrachromosomal DNA molecules 
which are present in bacterial cells and which have become the most common genetic 
engineering material. To ensure “targeted delivery” of plasmid-based DNA constructs, it 
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seems necessary to use transfection enhancement methods. It is known that DNA plasmid 
penetration into a transfected cell occurs by means of endocytosis (phagocytosis, pinocy-
tosis, receptor-mediated endocytosis). However, the process of endocytosis inside muscle 
fibers themselves is almost impossible; therefore, DNA plasmids are concentrated mainly 
in the cells of muscle environment.
One of the major disadvantages of plasmid DNA (plDNA) application is low effi-
ciency of its transfection and expression of the target protein, which jointly characterize 
bioavailability of genetic construct. To obtain the target bioavailability when extrapolating 
a potential therapeutic effect in humans after injection of genetic plDNA-based agents, 
it is necessary to use transfection increase methods, among which physical (electropora-
tion) transfection is considered to be high-demand one [12].
Objective of the study — the purpose of the study is to study the dynamics of NGF 
plDNA concentration and the level of its expression after intramuscular injection to ani-
mals using electroporation method.
Materials and methods of the study — experiments were performed on 500 white 
outbred male rats weighing 180–220 g, supplied by “Rappolovo” breeding station (Lenin-
grad region). The animals were kept in standard vivarium conditions at normal diet with 
free access to water. Previously, they all were in quarantine for at least 14 days.
Sample of plDNA recombinant encoding NGF production was used as a solution 
(manufactured by OJSC “ATG Service Gene”, Russia), presenting itself as rat NGF gene 
expression vector under control of early cytomegalovirus gene promoter. PlDNA was 
injected intramuscularly conventionally and/or using electroporation method. For elec-
troporation was used NEPA21 instrument (Nepagen, Japan). Before performing this tech-
nique, animals were anesthetized with a 5 % solution of sevoflurane by means of hard-
ware-software complex for artificial lung ventilation: “Single channel anesthesia system”, 
Kent Scientific Corporation (USA). PlDNA was injected to rats in a volume of 0.1 ml per 
1 kg of animal body weight at a dose of 250 μg/kg. Preparation dose was administered in 
three successive injections into the right tibial muscle at a distance of 2–3 mm from each 
other. Immediately after the introduction of the plasmid, an electrical discharge was ap-
plied with the following parameters:
 — pore forming effect (voltage — 250 V, pulse duration — 8 ms, pulse interval — 
50 ms, number of pulses — 2, attenuation — 40 %, without reversing electrodes 
the polarity (+));
 — transfer effect (voltage — 50 V, pulse duration — 50 ms, pulse interval — 50 ms, 
number of pulses — 9, attenuation — 40 %, with reversing electrodes the polarity 
(+/–)).
Analysis of plDNA concentration was carried out using equation, which allows to 
calculate DNA and RNA amount in blood and muscle tissue taken from animals before 
(intact indicators) and 1, 2, 4, 6, 8, 24 hours after its intramuscular injection. 10–30 mg 
of tissue homogenate or 250 μL of whole blood were used for the analysis. Tissue sam-
ples were homogenized using a homogenizer or by grinding in a mortar with micronized 
quartz sand.
DNA extraction was performed in accordance with instructions for DNA-sorb B kit. 
RNA extraction from tissues was performed using the TRI Reagent kit (manufactured 
by Sigma) according to manufacturer’s instructions. The cDNA synthesis was performed 
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using the Revert Aid® First Strand cDNA Synthesis Kit manufactured by “Fermentas”. 
To measure the relative content of mRNA, RealTime PCR with SYBR GREEN (SYBR 
Green Supermix (Bio-Rad)) was used. All the samples were normalized to the level of 
glyceraldehyde-3-phosphate dihydrogenase (GAPDH) gene expression. The reaction was 
performed using an IQ5  (“Bio-Rad”) thermal cycler, the data were analyzed using the 
enclosed software.
The following parameters obtained using the Thermo Kinetica 5.1 program (Thermo-
ElectronCorporation, USA) were used to estimate pharmacokinetic properties:
 — AUCtot (ng/ml * min) — the area under the concentration-time curve. It is de-
termined by diagram construction in “concentration-time” coordinates, the area 
under the curve being calculated;
 — total clearance (Cl, ml/min) — determines the amount of test tissue released from 
the substance per unit of time and calculated as the ratio of substance dose (D) to 
AUCtot;
 — MRT average retention time in test tissue;
 — stationary distribution volume (Vss, l) — proportionality coefficient between sub-
stance concentration in test chamber and its body amount. It reflects substance 
distribution intensity between test chambers; 
 — half-life (T1/2, min) — a period of time during which substance’s concentration 
reduces by half; 
 — absorption rate constant is exponent characterizing the rate at which substance 
enters bloodstream from injection site.
Efficiency of plDNA application was studied using experimental model of toxic 
neuropathy caused by subacute (daily for 3  days) intragastric intoxication of rats by 
malathion at dose equals 0.5 LD50. Indirect electroneuromyography (ENMG) method 
was used to estimate extent of damage caused to the peripheral nervous system. Motor 
response threshold (mA), amplitude (mV), area under the curve (mV * ms) and M-
response duration (ms) were determined [13]. Parameters were registered in dynamics 
in 1, 2, 3 weeks after toxicant injections.
Statistical analysis was carried out using the Statistica 10 program. Calculations of 
central tendencies and dispersion measures were carried out by common statistical meth-
ods. Normalcy distribution verification of actual data was performed using the Shapiro — 
Wilk criterion. Mann — Whitney, Wilcoxon and Kruskal — Wallis non-parametric crite-
ria were used to compare mean values and to identify significant differences. Differences 
were considered statistically significant at p <0.05.
Study Results and Discussion
The efficiency of plasmid DNA use is determined by its transfection degree and trans-
position near the cell nucleus, and kinetics of presence in the body was determined by 
endogenic DNA-ase effect immunity. The bioavailability of recombinant NGF plDNA was 
assessed by parameters of DNA content kinetics in quadriceps muscle tissue (injection 
site) and in rat blood, as well as by relative level of expression and specific protein accu-
mulation over time. Comparative analysis of DNA concentration in muscle tissue to assess 
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the efficiency of electroporation aimed to increase bioavailability of recombinant NGF 
plDNA was performed (Fig.).
One hour after i/m injection of recombinant NGF plDNA to rats, maximum concen-
tration of DNA in blood was observed: 4.5 ± 0.47 μg/ml. DNA concentration in muscle at 
the same period was 1.1 ± 0.46 µg/mg tissue. Later (24 hours) DNA in blood was observed 
in trace amounts.
The data shown in Figure reliably confirm higher bioavailability indices when us-
ing the electroporation method. Estimated pharmacokinetics data of recombinant NGF 
plDNA using electroporation are shown in Table 1.
Table 1. Pharmacokinetic parameters of DNA in blood and quadriceps muscle of rats 
after intramuscular injection and intramuscular injection using the method of electroporation 











AUCtot, h*µg/ml 5,6 ± 1,12 3,9 ± 1,21* 12,8 ± 3,21 39 ± 9,66*
T1/2, h 2,8 ± 0,76  3,3 ± 1,01  5,7 ± 1,8  5,0 ± 1,65 
MRT, h 4,5 ± 0,96  5,0 ± 1,32  9,5 ± 2,1  8,2 ± 2,31 
Cl, ml-1  35,5 ± 10,4  51,4 ± 12,3* 15,6 ± 3,76  5,1 ± 1,7* 
Vss, ml 160 ± 35  257 ± 87  149 ± 34,2  42 ± 8,93* 
Kel, h-1  0,25 ± 0,05  0,21 ± 0,04  0,12 ± 0,03  0,14 ± 0,02 
N o t e: * — differences related to “without electroporation” group are statistically significant at р < 0,05.
Fig. Comparative analysis of the DNA concentration in rat muscle tissue after i/m 
injection and i/m injection using the method of electroporation of recombinant NGF plDNA 
at a dose of 250 µg/kg, n = 10 
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Obtained data confirms that electroporation method improves DNA penetration in 
muscle (target) tissue and, as a result, reduces the amount of sample that penetrates in 
blood from the injection site. The ratio of the area under the pharmacokinetic curve in 
muscle to the area in blood using electroporation constitutes 39, without electropora-
tion  — 12.8. Data from different pharmacokinetics of recombinant plDNA were con-
firmed by obtained results of relative level of RNA expression (Table 2).
Table 2. Dynamics of the relative expression level in rat muscle tissue after i/m injection 
and i/m injection using electroporation method of recombinant NGF plDNA at a dose of 250 μg/kg 















1  8/8  13,4 ± 7,07  8/8  29,6 ± 10,67 
2  8/8  28,1 ± 18,59  8/8  152,5 ± 12,9* 
4  8/8  22,63 ± 8,57  8/8  149,3 ± 21,03* 
6  8/8  20,9 ± 5,43  8/8  83,4 ± 9,92* 
8  8/8  17,0 ± 2,75  8/8  56,8 ± 9,64 
24  7/8  7,77 ± 5,65  8/8  18,9 ± 2,86 
N o t e: * — differences between groups are statistically significant at р < 0,05.
In comparative analysis of this indicator after 24 hours the differences between groups 
reached 3 times values, which evidenced a longer presence of target DNA inside the cell 
and, as a result, a longer duration of transcription processes. A higher level of transfec-
tion of recombinant NGF plDNA using electroporation was proved by concentration of a 
specific protein (Table 3).
Table 3. Concentration of NGF (pg/ml) in rat blood plasma after i/m injection and i/m injection 
using electroporation method of recombinant NGF plasmid DNA at a dose of 250 μg/kg at different 
observation times (n = 10, M ± SD )
Group
Observation time, h 
4 8 24
Control (physical solution) 0 ± 0  0 ± 0  0 ± 0 
NGF plDNA i/m 10,4 ± 3,96* 5,2 ± 0,98* 0,1 ± 0,09 
NGF plDNA i/m with electroporation 28,0 ± 8,97*∆ 17,4 ± 5,46*∆ 0,5 ± 0,32 
N o t e s: 1) * — differences from control group are statistically significant at р < 0,05; 2)  ∆ — differences 
between recombinant NGF plDNA groups are statistically significant at р < 0,05.
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So in course of studying this indicator in the period of maximum level of relative ex-
pression (4 h), high (more than 3 times) indicators were reported when using electropora-
tion method in comparison with i/m injection of recombinant NGF plDNA.
Application of electroporation ensured an earlier improvement in ENMG parameters 
(Table 4).
Table 4. Dependence of neuromuscular conduction disorders after intragastric injection of malathion 
at a dose of 0.5 LD50 and intramuscular injection of NGF RPD at a dose of 250 µg/kg using the 
electroporation method (М ± mм, n = 8) 















Control of intoxication 
Background 0,6 ± 0,01 
(0 ± 8) 
1,8 ± 0,01 
(0 ± 8) 
25,5 ± 0,11 
(0 ± 8) 
24,2 ± 0,09 
(0 ± 8) 
1,9 ± 0,02 
(0 ± 8) 
14th day 0,7 ± 0,01 
(42 ± 15)* 
1,7 ± 0,02 
(50 ± 15)* 
23,5 ± 0,1 
(66 ± 15)** 
27,2 ± 0,28 
(58 ± 15)** 
2 ± 0,03 
(42 ± 15)* 
21st day 0,7 ± 0,01 
(58 ± 15)* 
1,6 ± 0,03 
(50 ± 15)* 
23 ± 0,13 
(75 ± 13)*** 
28 ± 0,31 
(66 ± 15)** 
2,1 ± 0,02 
(50 ± 15)* 
28th day 0,7 ± 0,02 
(66 ± 15)** 
1,6 ± 0,02 
(66 ± 15)** 
22,5 ± 0,09 
(75 ± 13)*** 
28,4 ± 0,48 
(66 ± 15)** 
2,2 ± 0,02 
(58 ± 15)** 
Experiment 1 (i/m injection of NGF RPD) 
Background 0,6 ± 0,01 
(0 ± 8) 
1,8 ± 0,01
(0 ± 8) 
25,5 ± 0,11 
(0 ± 8) 
24,2 ± 0,09
(0 ± 8) 
1,8 ± 0,02 
(0 ± 8) 
14th day 0,7 ± 0,01 
(42 ± 15)* 
1,6 ± 0,02 
(50 ± 15)* 
23,4 ± 0,1 
(42 ± 15)* 
29,2 ± 0,28 
(50 ± 15)* 
2,2 ± 0,03 
(50 ± 15)* 
21st day 0,7 ± 0,01
(33 ± 15) 
1,7 ± 0,03 
(42 ± 15)* 
24,5 ± 0,13 
(25 ± 13) 
26,6 ± 0,31 
(33 ± 15) 
2,1 ± 0,02 
(33 ± 15) 
8th day 0,6 ± 0,02∆ 
(25 ± 13∆) 
1,8 ± 0,02∆ 
(33 ± 15) 
25,1 ± 0,09 
(25 ± 13∆) 
24,8 ± 0,48∆ 
(25 ± 13∆) 
1,9 ± 0,02∆ 
(17 ± 11∆) 
Experiment 2 (i/m injection of NGF RPD using electroporation method)
Background 0,6 ± 0,02 
(0 ± 8) 
1,8 ± 0,02 
(0 ± 8) 
25,8 ± 0,12 
(0 ± 8) 
25,1 ± 0,29 
(0 ± 8)
1,9 ± 0,02 
(0 ± 8)
14th day 0,7 ± 0,02 
(33 ± 15) 
1,7 ± 0,04 
(42 ± 15)* 
24,6 ± 0,1 
(42 ± 15)* 
26,1 ± 0,37 
(33 ± 15) 
2,1 ± 0,01 
(33 ± 15)
21st day 0,6 ± 0,02∆ 
(25 ± 13) 
1,8 ± 0,02 
(33 ± 15) 
25,2 ± 0,13∆ 
 (25 ± 13∆) 
25,7 ± 0,38∆ 
(17 ± 11∆) 
2,0 ± 0,01 
(25 ± 13)
28th day 0,7 ± 0,01 
(17 ± 11∆) 
1,8 ± 0,01 
(25 ± 13∆)
25,6 ± 0,09∆ 
 (17 ± 11∆) 
25,2 ± 0,44 
(17 ± 11∆) 
1,9 ± 0,02 
(17 ± 11∆) 
N o t e: 1)  incidence of animals with the parameter deviation as compared to total number of animals is shown 
in brackets; 2)  * — differences in respect to the background are significant at р ≥ 0.05; 3)  ** — differences in respect to 
the background are significant at p ≤ 0.01;  4) *** — differences in respect to the background are significant at p ≤ 0.001; 
5) ∆ — differences in respect to the control are significant at p ≤ 0.05;
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Restoration of neuromuscular conduction parameters in the group with isolated in-
tramuscular injection was slower. By the 14th day, according to such parameters as maxi-
mum M-response and amplitude of the M-response, neuromuscular conduction disorders 
were observed in a half of the animals in this group. The partial restoration of ENMG pa-
rameters was observed by the 21st day, however, by this time the number of animals with 
the parameter deviation from the intra species standard was greater than in the group 
where electroporation method was used.
Recombinant plasmids DNA NGF reliably prevent ENMG disorder development af-
ter subacute poisoning by malathion in dose equals 0.5 LD50. Application of electropo-
ration method enables to achieve ENMG parameters growth by the 14th day after in-
toxication. Our findings allow considering the electroporation method to be a promising 
approach for the delivery of plasmid DNA encoding the accumulation of nerve growth 
factor for prevention of peripheral neuropathy.
Thereby, in course of this study, appropriateness of electroporation method in in-
crease of bioavailability and effectiveness of plasmid DNA encoding nerve growth factor 
was justified.
Conclusion
1. Electroporation method, due to increase of bioavailability by 1.5  times, as well 
as relative level of expression of gene encoding NGF production by 3 times, and 
3 times increase in concentration of target NGF protein in blood plasma, signifi-
cantly increases efficiency of plDNA activity.
2. Obtained results enable us to recommend electroporation method for the injec-
tion of NGF plDNA for investigation its biological activity and efficiency in simu-
lated nerve damages.
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